2026-03-16 20:09:29
Assertio Holdings Reports Q4 and FY2025 Financial Results with Decline in Rolvedon Sales
Expected Stock impact: Slightly Negative
On March 16, 2026, Assertio Holdings, Inc. (Nasdaq: ASRT) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported a significant decline in net product sales for its core asset, Rolvedon, which fell to $0.4 million in Q4 2025 from $15.4 million in the same quarter of the previous year. This decline was attributed to a sell-in executed in Q3 2025, which was intended to ensure uninterrupted patient supply during a transition to a new distribution partner. Despite this setback, Assertio's other product, Sympazan, saw an increase in sales, growing to $3.1 million in Q4 2025 from $2.5 million in the prior-year quarter. The company reported a net loss of $11.9 million for Q4 2025, compared to a loss of $10.5 million in Q4 2024. For the full year 2025, Assertio's net product sales totaled $68.2 million, up from $60.1 million in 2024. The company also provided guidance for FY2026, expecting net product sales between $110 million and $125 million and adjusted EBITDA between $28 million and $40 million. CEO Mark Reisenauer emphasized the importance of leveraging core strengths and building a differentiated oncology franchise to drive shareholder value. The company’s cash and cash equivalents stood at $63.4 million as of December 31, 2025, down from $93.4 million at the end of Q3 2025, reflecting the impacts of the Rolvedon sell-in. Assertio's management will host a conference call to discuss these results and the company's outlook for the future.
